Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors
Status:
Completed
Trial end date:
2019-10-29
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the potential of
Al18F-1,4,7-triazacyclononane-1,4,7-triacetate-octreotide (Al18F-NOTA-octreotide) as a
positron emission tomography (PET) somatostatin receptor imaging agent in patients with
neuroendocrine tumors.